Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Statistics in Medicine|April 2, 2026
Randomization-Based Covariance Analysis for Confidence Intervals of Treatment Comparisons Based on Restricted Mean Survival Time With Categorized Time-to-Event DataTaylor Krajewski, Gary Koch
Statistical Methods in Medical Research|February 6, 2024
The augmented synthetic control method in public health and biomedical researchTaylor Krajewski, Michael Hudgens
Journal of Correctional Health Care : the Official Journal of the National Commission on Correctional Health Care|December 27, 2023
Documenting Competing Needs to Well-Being Among Those on Community Supervision in the SouthKatherine LeMasters, Taylor Krajewski, Kimberly Dong, et al.
Pharmaceutical Statistics|January 12, 2017
Analyzing multiple endpoints in a confirmatory randomized clinical trial-an approach that addresses stratification, missing values, baseline imbalance and multiplicity for strictly ordinal outcomesHengrui Sun, Atsushi Kawaguchi, Gary Koch
AIDS Care|August 1, 2024
Perceived versus actual HIV risk among PrEP indicated persons with criminal legal involvementTaylor Krajewski, Katherine H LeMasters, Carrie B Oser, et al.
Therapeutic Innovation & Regulatory Science|March 23, 2022
Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's DiseaseDeli Wang, Elaine Kearney Kowalewski, Gary Koch
Pharmaceutical Statistics|April 10, 2014
The iterative proportional fitting algorithm for adjusted agreement in a non-inferiority diagnostic clinical trialJill Ann El-Khorazaty, Gary Koch, John Preisser
Therapeutic Innovation & Regulatory Science|April 2, 2021
Design and Analysis of a Biosimilar Bridging Study with a Prediction Interval-Based Consistency TestZhiying Pan, Wenying Huang, Jianhong Pan, et al.
AIDS Care|April 4, 2022
Context specific HIV risk: evidence from screening into the southern pre-exposure prophylaxis study (SPECS)Katherine LeMasters, Taylor Krajewski, Kathryn Nowotny, et al.
Pharmaceutical Statistics|May 5, 2017
Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case studyJohn Ouyang, Kevin J Carroll, Gary Koch, et al.
Pageof 5